Systematic review: Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Background: Five proton pump inhibitors are now available for use in North America. Claims of differences in the clinical efficacy of different strengths and/or agents have been made. Aim: To identify any consistent evidence of differences in outcomes between agents or doses within this class of drugs. Methods: A search of the medical literature was performed in two electronic databases, and randomized controlled trials of higher quality were included in the assessment. Results and conclusions: Thirty-two trials met our criteria. No convincing data were found to indicate that low doses of proton pump inhibitors are as effective as standard doses of proton pump inhibitors in the healing of erosive oesophagitis or in the relief of symptoms of gastro-oesophageal reflux disease; however, they may be as effective as maintenance therapy for gastro-oesophageal reflux disease and peptic ulcer disease. Differences were found between the standard doses of proton pump inhibitors with regard to the onset of symptom relief in gastro-oesophageal reflux disease (lansoprazole was faster than omeprazole, and esomeprazole was faster than both lansoprazole and omeprazole) and the healing of oesophagitis (esomeprazole was superior to both omeprazole and lansoprazole). Despite these differences, there are as yet insufficient data to establish the superiority of any one agent over all others across all disease states treated with these agents.

Original languageEnglish (US)
Pages (from-to)559-568
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume18
Issue number6
DOIs
StatePublished - Sep 15 2003

Fingerprint

Esophageal Diseases
Proton Pump Inhibitors
Gastroesophageal Reflux
Lansoprazole
Peptic Ulcer
Omeprazole
Esomeprazole
Esophagitis
North America
Randomized Controlled Trials
Databases
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{192e58b320454058ab6495ea58857f93,
title = "Systematic review: Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease",
abstract = "Background: Five proton pump inhibitors are now available for use in North America. Claims of differences in the clinical efficacy of different strengths and/or agents have been made. Aim: To identify any consistent evidence of differences in outcomes between agents or doses within this class of drugs. Methods: A search of the medical literature was performed in two electronic databases, and randomized controlled trials of higher quality were included in the assessment. Results and conclusions: Thirty-two trials met our criteria. No convincing data were found to indicate that low doses of proton pump inhibitors are as effective as standard doses of proton pump inhibitors in the healing of erosive oesophagitis or in the relief of symptoms of gastro-oesophageal reflux disease; however, they may be as effective as maintenance therapy for gastro-oesophageal reflux disease and peptic ulcer disease. Differences were found between the standard doses of proton pump inhibitors with regard to the onset of symptom relief in gastro-oesophageal reflux disease (lansoprazole was faster than omeprazole, and esomeprazole was faster than both lansoprazole and omeprazole) and the healing of oesophagitis (esomeprazole was superior to both omeprazole and lansoprazole). Despite these differences, there are as yet insufficient data to establish the superiority of any one agent over all others across all disease states treated with these agents.",
author = "N. Vakil and Fennerty, {M (Brian)}",
year = "2003",
month = "9",
day = "15",
doi = "10.1046/j.1365-2036.2003.01756.x",
language = "English (US)",
volume = "18",
pages = "559--568",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Systematic review

T2 - Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease

AU - Vakil, N.

AU - Fennerty, M (Brian)

PY - 2003/9/15

Y1 - 2003/9/15

N2 - Background: Five proton pump inhibitors are now available for use in North America. Claims of differences in the clinical efficacy of different strengths and/or agents have been made. Aim: To identify any consistent evidence of differences in outcomes between agents or doses within this class of drugs. Methods: A search of the medical literature was performed in two electronic databases, and randomized controlled trials of higher quality were included in the assessment. Results and conclusions: Thirty-two trials met our criteria. No convincing data were found to indicate that low doses of proton pump inhibitors are as effective as standard doses of proton pump inhibitors in the healing of erosive oesophagitis or in the relief of symptoms of gastro-oesophageal reflux disease; however, they may be as effective as maintenance therapy for gastro-oesophageal reflux disease and peptic ulcer disease. Differences were found between the standard doses of proton pump inhibitors with regard to the onset of symptom relief in gastro-oesophageal reflux disease (lansoprazole was faster than omeprazole, and esomeprazole was faster than both lansoprazole and omeprazole) and the healing of oesophagitis (esomeprazole was superior to both omeprazole and lansoprazole). Despite these differences, there are as yet insufficient data to establish the superiority of any one agent over all others across all disease states treated with these agents.

AB - Background: Five proton pump inhibitors are now available for use in North America. Claims of differences in the clinical efficacy of different strengths and/or agents have been made. Aim: To identify any consistent evidence of differences in outcomes between agents or doses within this class of drugs. Methods: A search of the medical literature was performed in two electronic databases, and randomized controlled trials of higher quality were included in the assessment. Results and conclusions: Thirty-two trials met our criteria. No convincing data were found to indicate that low doses of proton pump inhibitors are as effective as standard doses of proton pump inhibitors in the healing of erosive oesophagitis or in the relief of symptoms of gastro-oesophageal reflux disease; however, they may be as effective as maintenance therapy for gastro-oesophageal reflux disease and peptic ulcer disease. Differences were found between the standard doses of proton pump inhibitors with regard to the onset of symptom relief in gastro-oesophageal reflux disease (lansoprazole was faster than omeprazole, and esomeprazole was faster than both lansoprazole and omeprazole) and the healing of oesophagitis (esomeprazole was superior to both omeprazole and lansoprazole). Despite these differences, there are as yet insufficient data to establish the superiority of any one agent over all others across all disease states treated with these agents.

UR - http://www.scopus.com/inward/record.url?scp=0141650562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141650562&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2003.01756.x

DO - 10.1046/j.1365-2036.2003.01756.x

M3 - Article

C2 - 12969082

AN - SCOPUS:0141650562

VL - 18

SP - 559

EP - 568

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 6

ER -